2024 |
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database |
Review essay (rassegna critica) |
Vai |
2024 |
Evaluation of predictive factors for i-CLARAS (intraoperative complications in laparoscopic renal and adrenal surgery): a multicentre international retrospective cohort study |
Articolo in rivista |
Vai |
2024 |
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” |
Articolo in rivista |
Vai |
2024 |
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer |
Articolo in rivista |
Vai |
2024 |
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors |
Review essay (rassegna critica) |
Vai |
2024 |
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients |
Articolo in rivista |
Vai |
2024 |
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors |
Articolo in rivista |
Vai |
2024 |
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group |
Articolo in rivista |
Vai |
2023 |
Gastrointestinal Stromal Tumors: Diagnosis, Follow-up and Role of Radiomics in a Single Center Experience |
Articolo in rivista |
Vai |
2023 |
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? |
Articolo in rivista |
Vai |
2023 |
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
Articolo in rivista |
Vai |
2023 |
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay |
Articolo in rivista |
Vai |
2023 |
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group |
Articolo in rivista |
Vai |
2023 |
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? |
Articolo in rivista |
Vai |
2023 |
The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine |
Articolo in rivista |
Vai |
2023 |
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) |
Articolo in rivista |
Vai |
2023 |
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis |
Review essay (rassegna critica) |
Vai |
2023 |
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study |
Articolo in rivista |
Vai |
2023 |
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST) |
Articolo in rivista |
Vai |
2023 |
CT and MR Imaging of Retroperitoneal Sarcomas: A Practical Guide for the Radiologist |
Review essay (rassegna critica) |
Vai |
2022 |
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel |
Articolo in rivista |
Vai |
2022 |
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement |
Articolo in rivista |
Vai |
2022 |
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses |
Articolo in rivista |
Vai |
2022 |
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial |
Articolo in rivista |
Vai |
2022 |
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis |
Articolo in rivista |
Vai |
2022 |
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors |
Articolo in rivista |
Vai |
2022 |
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study |
Articolo in rivista |
Vai |
2022 |
Liquid biopsy and immunotherapy: is all that glitter gold? |
Capitolo o Saggio |
Vai |
2022 |
Molecular tumor board |
Capitolo o Saggio |
Vai |
2022 |
Future perspectives |
Capitolo o Saggio |
Vai |
2022 |
Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network |
Articolo in rivista |
Vai |
2022 |
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints |
Articolo in rivista |
Vai |
2022 |
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography |
Articolo in rivista |
Vai |
2022 |
Current clinically validated applications of liquid biopsy |
Capitolo o Saggio |
Vai |
2021 |
Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic |
Articolo in rivista |
Vai |
2021 |
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study |
Articolo in rivista |
Vai |
2021 |
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study |
Articolo in rivista |
Vai |
2021 |
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? |
Articolo in rivista |
Vai |
2021 |
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic |
Articolo in rivista |
Vai |
2021 |
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study |
Articolo in rivista |
Vai |
2021 |
Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group |
Articolo in rivista |
Vai |
2021 |
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network |
Articolo in rivista |
Vai |
2021 |
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors |
Review essay (rassegna critica) |
Vai |
2021 |
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study |
Articolo in rivista |
Vai |
2021 |
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon |
Articolo in rivista |
Vai |
2021 |
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) |
Articolo in rivista |
Vai |
2021 |
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge |
Articolo in rivista |
Vai |
2021 |
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome |
Articolo in rivista |
Vai |
2021 |
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors |
Articolo in rivista |
Vai |
2020 |
Fatal heart failure induced by pazopanib in a sarcoma patient previously treated with gemcitabine |
Articolo in rivista |
Vai |
2020 |
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes |
Articolo in rivista |
Vai |
2020 |
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
Articolo in rivista |
Vai |
2020 |
Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report |
Articolo in rivista |
Vai |
2020 |
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience |
Articolo in rivista |
Vai |
2020 |
Recent advances in desmoid tumor therapy |
Articolo in rivista |
Vai |
2020 |
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) |
Articolo in rivista |
Vai |
2020 |
Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma |
Articolo in rivista |
Vai |
2020 |
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor |
Articolo in rivista |
Vai |
2020 |
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retrospective analysis |
Articolo in rivista |
Vai |
2020 |
Perioperative chemotherapy in poorly differentiated neuroendocrine neoplasia of the bladder: A multicenter analysis |
Articolo in rivista |
Vai |
2020 |
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions |
Articolo in rivista |
Vai |
2020 |
Delaying surgery for patients with a previous SARS-CoV-2 infection |
Lettera |
Vai |
2020 |
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients |
Articolo in rivista |
Vai |
2020 |
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming |
Articolo in rivista |
Vai |
2020 |
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections |
Articolo in rivista |
Vai |
2019 |
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis |
Articolo in rivista |
Vai |
2019 |
CT and MR imaging of chemotherapy-induced hepatopathy |
Articolo in rivista |
Vai |
2019 |
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients |
Articolo in rivista |
Vai |
2019 |
Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report |
Articolo in rivista |
Vai |
2019 |
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients |
Articolo in rivista |
Vai |
2019 |
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2019 |
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group |
Articolo in rivista |
Vai |
2019 |
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials |
Articolo in rivista |
Vai |
2019 |
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis |
Articolo in rivista |
Vai |
2019 |
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? |
Review essay (rassegna critica) |
Vai |
2019 |
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives |
Articolo in rivista |
Vai |
2019 |
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) |
Nota o commento |
Vai |
2019 |
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 |
Articolo in rivista |
Vai |
2019 |
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials |
Articolo in rivista |
Vai |
2019 |
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Review essay (rassegna critica) |
Vai |
2019 |
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy |
Articolo in rivista |
Vai |
2019 |
Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients |
Articolo in rivista |
Vai |
2019 |
Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters |
Articolo in rivista |
Vai |
2019 |
Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes |
Articolo in rivista |
Vai |
2019 |
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? |
Articolo in rivista |
Vai |
2018 |
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors |
Articolo in rivista |
Vai |
2018 |
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study |
Articolo in rivista |
Vai |
2018 |
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib |
Articolo in rivista |
Vai |
2018 |
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis |
Articolo in rivista |
Vai |
2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial |
Articolo in rivista |
Vai |
2018 |
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) |
Nota o commento |
Vai |
2018 |
Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin |
Articolo in rivista |
Vai |
2017 |
Liquid Biopsy in Gastrointestinal Stromal Tumor |
Capitolo o Saggio |
Vai |
2017 |
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives |
Articolo in rivista |
Vai |
2017 |
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice |
Articolo in rivista |
Vai |
2017 |
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas |
Articolo in rivista |
Vai |
2016 |
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma |
Articolo in rivista |
Vai |
2016 |
Erratum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (Scientific Reports (2015) 5 (18670) DOI: 10.1038/srep18670) |
Nota o commento |
Vai |
2016 |
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond |
Articolo in rivista |
Vai |
2016 |
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report |
Articolo in rivista |
Vai |
2015 |
Targeted Therapies in Gastrointestinal Stromal Tumors |
Capitolo o Saggio |
Vai |
2015 |
Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study |
Articolo in rivista |
Vai |
2015 |
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? |
Articolo in rivista |
Vai |
2015 |
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis |
Articolo in rivista |
Vai |
2015 |
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers |
Proceedings |
Vai |
2015 |
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases |
Articolo in rivista |
Vai |
2014 |
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour |
Articolo in rivista |
Vai |
2013 |
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma |
Articolo in rivista |
Vai |
2013 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. |
Articolo in rivista |
Vai |
2013 |
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
Articolo in rivista |
Vai |
2013 |
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. |
Articolo in rivista |
Vai |
2012 |
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study |
Articolo in rivista |
Vai |
2012 |
PML expression in soft tissue sarcoma: Prognostic and predictive value in
alkylating agents/antracycline-based first line therapy. |
Articolo in rivista |
Vai |
2011 |
EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE |
Proceedings |
Vai |
2010 |
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results |
Proceedings |
Vai |
2010 |
PML down-regulation in soft tissue sarcomas. |
Articolo in rivista |
Vai |
2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a
second-/third-line chemotherapy in advanced adrenocortical carcinoma: a
multicenter phase II study. |
Articolo in rivista |
Vai |
2010 |
Serum follistatin in patients with prostate cancer metastatic to the bone |
Articolo in rivista |
Vai |
2010 |
PML down-regulation in soft tissue sarcomas |
Articolo in rivista |
Vai |
2010 |
EFFICACY OF ZOLEDRONIC ACID IN PATIENTS
WITH COLORECTAL CANCER METASTATIC TO BONE |
Proceedings |
Vai |
2010 |
PML expression in soft tissue sarcoma: prognostic value in alkilating agents/anthracyclin based first line therapy |
Proceedings |
Vai |
2009 |
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. |
Articolo in rivista |
Vai |
2009 |
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide |
Abstract in rivista |
Vai |
2009 |
Comparison between palonosetron(P) and aprepitant (A) versus palonosetron alone for antiemetic prophylaxis in advanced soft tissue sarcoma (STS)patients treated with epirubicin and ifosfamide. |
Abstract in rivista |
Vai |
2009 |
GIST, Tumori stromali gastrointestinali (Gist: linee guida diagnostico-terapeutiche) |
Monografia |
Vai |
2008 |
Gemcitabine plus metronoic capecitabine as second/third line chemotherapy in advanced adrenocortical carcinoma. A multicenter phase II trial. |
Abstract in rivista |
Vai |
2008 |
Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. |
Capitolo o Saggio |
Vai |
2008 |
The Use of Lenograstim in the prevention of chemotherapy induced neutropenia in patiets with soft tissue sarcoma (STS) |
Proceedings |
Vai |
2008 |
Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (P) as second line chemotherapy in metastatic bladder cancer. |
Abstract in rivista |
Vai |
2008 |
Antifungal prophylaxis of oropharyngeal mucositis with itraconazole during adjuvant chemotherapy in colorectal cancer (CRC)patients. |
Abstract in rivista |
Vai |
2007 |
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. |
Articolo in rivista |
Vai |
2007 |
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management
designs and issues in diagnosis. |
Articolo in rivista |
Vai |
2007 |
Founder mutations in BRCA1 and BRCA2 genes |
Articolo in rivista |
Vai |
2007 |
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. |
Proceedings |
Vai |
2007 |
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). |
Articolo in rivista |
Vai |
2007 |
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and
biomolecular features |
Articolo in rivista |
Vai |
2007 |
The role of Aurora-A inhibitors in cancer therapy. |
Articolo in rivista |
Vai |
2006 |
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. |
Proceedings |
Vai |
2006 |
GIST |
Proceedings |
Vai |
2006 |
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. |
Articolo in rivista |
Vai |
2006 |
A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy |
Articolo in rivista |
Vai |
2006 |
Ductal lavage: a way of carefully tracing the breast-secreting duct |
Articolo in rivista |
Vai |
2006 |
A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. |
Articolo in rivista |
Vai |
2006 |
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma |
Articolo in rivista |
Vai |
2006 |
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report |
Proceedings |
Vai |
2006 |
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer |
Proceedings |
Vai |
2006 |
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread |
Proceedings |
Vai |
2006 |
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers |
Articolo in rivista |
Vai |
2006 |
Activin a and matrix metalloproteinase-2 and -9 blood levels as gauges of bone metastatic spread. In: Tumor microenvironment:Heterotypic interactions. |
Proceedings |
Vai |
2006 |
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. |
Articolo in rivista |
Vai |
2006 |
P16 ink4A, p53 alterations and S phase fraction are predictive of clinical outcome in laryngeal squamous cell carcinoma. |
Proceedings |
Vai |
2006 |
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation |
Proceedings |
Vai |
2006 |
Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer. |
Proceedings |
Vai |
2006 |
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer |
Articolo in rivista |
Vai |
2006 |
Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance |
Proceedings |
Vai |
2006 |
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. |
Proceedings |
Vai |
2005 |
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER |
Articolo in rivista |
Vai |
2005 |
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers |
Articolo in rivista |
Vai |
2005 |
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer |
Proceedings |
Vai |
2005 |
The use of somatostatin analogues in metastatic hormone refractory and chemo resistant prostate cancer with neuroendocrine differentiation. |
Proceedings |
Vai |
2005 |
Surgical Treatment of Extravasation Injuries |
Articolo in rivista |
Vai |
2004 |
Cardiotossicità e Cardioprotezione. |
Altro |
Vai |
2004 |
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation |
Proceedings |
Vai |
2004 |
A phase II study of Oxaliplatin Capecitabine chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes |
Proceedings |
Vai |
2004 |
Weekly paclitaxel and Pegylated liposomal doxorubicin as first line treatment in metastatic breast cancer patients |
Proceedings |
Vai |
2004 |
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 |
Proceedings |
Vai |
2004 |
Zoledronic acid-induced variations in MMP-2, MMP-9 and uPA plasma concentrations in patients with metastatic bone disease |
Proceedings |
Vai |
2004 |
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer |
Proceedings |
Vai |
2004 |
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 |
Proceedings |
Vai |
2004 |
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes |
Proceedings |
Vai |
2004 |
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer |
Proceedings |
Vai |